Clinical trials: Dupilumab
Dermatitis Atopic
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Primary Objective: Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus.
- Trial name
- DIFFEREN-STAD (NCT04823130)
- Testing
- Dupilumab (SAR231893)
- Where
- 3 sites in United States, Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Gastrointestinal Disorders (EGIDs)
Dupilumab Therapy for EGIDs
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
- Trial name
- NCT07257835
- Testing
- Dupilumab - Standard Dose, subcutaneous injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Fudan University
Wheezing, Asthma
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze.
- Trial name
- NCT06191315
- Testing
- Dupilumab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Sanofi
Asthma
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment…
- Trial name
- REVEAL (NCT04550962)
- Testing
- Dupilumab SAR231893
- Where
- 41 sites in Argentina, Chile and 10 more
- Volunteers
- 376 people
- Sponsor
- Sanofi
Healthy Volunteers
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetic of 2 different dupilumab drug products in adult healthy volunteers. The duration per participant is up to 11 weeks.
- Trial name
- NCT05976373
- Testing
- Dupilumab (SAR231893)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Registry for Systemic Eczema Treatments
The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD.
- Trial name
- RESET (NCT06136767)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Johns Hopkins University
Keloid
Dupilumab in the Treatment of Keloids
This study is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will include a total of 44 subjects with clinically measurable keloid lesions.
- Trial name
- NCT04988022
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Allergic Contact Dermatitis
The Effects of Dupilumab on Allergic Contact Dermatitis
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
- Trial name
- NCT03935971
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Chronic Rhinosinusitis With Nasal Polyps
Mechanisms of Smell Improvement With Dupilumab.
This study seeks to explore the mechanism through which dupilumab improves olfactory cleft inflammation in patients with chronic sinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT05964465
- Testing
- Dupilumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Atopic Dermatitis
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).
- Trial name
- NCT01949311
- Testing
- Dupilumab
- Where
- 432 sites in United States, Australia and 26 more
- Volunteers
- 2,733 people
- Sponsor
- Regeneron Pharmaceuticals
Healthy Participants
A Phase I Study of 9MW4113 Injection Versus Dupixent®
It is a randomized, double-blinded, parallel, single-dose, Phase I comparative study to evaluate the pharmacokinetic, safety, and immunogenicity similarity between 9MW4113 and Dupixent® in healthy Chinese adult participants.
- Trial name
- NCT07791342
- Testing
- 9MW4113 injection, Dupilumab
- Where
- China
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Atopic Dermatitis
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects.
- Trial name
- NCT06614907
- Testing
- QL2108 injection, Dupixent®
- Where
- China
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Asthma
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
- Trial name
- NCT04203797
- Testing
- dupilumab
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with…
- Trial name
- ProMEAL (NCT06695897)
- Testing
- Dupilumab
- Where
- 15 sites in Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis
Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by intense pruritus and sleep disturbances. The clinical manifestations of AD are varied, with the most basic features being dry skin, chronic…
- Trial name
- NCT06465732
- Testing
- Dupilumab, Tofacitinib
- Volunteers
- 220 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hand Eczema
Dupilumab in Severe Chronic Hand Eczema
The purpose of this study is to investigate the efficacy of dupilumab in hand eczema patients with an inadequate response or intolerance to alitretinoin.
- Trial name
- DUPSHE (NCT04512339)
- Testing
- Dupilumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Atopic Dermatitis
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01385657
- Testing
- Dupilumab, Background treatment
- Where
- 13 sites in Australia, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Moderate to Severe Asthma
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment.
- Trial name
- EPIPHANY (NCT06385236)
- Testing
- Dupilumab, Benralizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, San Diego